Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Nervous System Neoplasms

ClinicalTrials.gov lists 4,072 trials for Nervous System Neoplasms or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 234.

MeSH D009423 Neoplasms Neoplasm C04 C10
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 785 Phase 1/2 Phase 1/2 289 Phase 2 Phase 2 959 Phase 2/3 Phase 2/3 38 Phase 3 Phase 3 275 Phase 4 Phase 4 74 Not applicable Not applicable 795 Observational Observational 835 Phase 1 Phase 1 785 Phase 1/2 Phase 1/2 289 Phase 2 Phase 2 959 Phase 2/3 Phase 2/3 38 Phase 3 Phase 3 275 Phase 4 Phase 4 74 Not applicable Not applicable 795 Observational Observational 835

Trials per phase (log scale)

2 more sections with rows

18 of the 4,072 trials are tagged with Nervous System Neoplasms itself; the rest are tagged with a narrower condition beneath it.

Get the Nervous System Neoplasms report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Nervous System Neoplasms trials start? (37)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 11 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational
  • Other (Expanded access, Unknown)

Top of scale: 231

1990: 1 trials (Phase 1 1) 1991: 4 trials (Observational 1, Phase 2 2, Phase 1 1) 1992: 6 trials (Observational 1, Phase 3 2, Phase 2 1, Phase 1 2) 1993: 5 trials (Not applicable 1, Phase 2 1, Phase 1/2 1, Phase 1 2) 1994: 15 trials (Observational 4, Not applicable 1, Phase 3 3, Phase 2 4, Phase 1 3) 1995: 16 trials (Observational 5, Not applicable 1, Phase 4 1, Phase 3 2, Phase 2 3, Phase 1/2 1, Phase 1 3) 1996: 22 trials (Observational 3, Not applicable 1, Phase 3 6, Phase 2 6, Phase 1 6) 1997: 39 trials (Other 1, Observational 5, Not applicable 2, Phase 3 4, Phase 2 16, Phase 1/2 1, Phase 1 10) 1998: 47 trials (Observational 3, Not applicable 1, Phase 3 5, Phase 2/3 1, Phase 2 21, Phase 1/2 4, Phase 1 12) 1999: 49 trials (Observational 4, Phase 3 5, Phase 2 26, Phase 1/2 2, Phase 1 12) 2000: 59 trials (Observational 4, Not applicable 3, Phase 4 1, Phase 3 3, Phase 2 23, Phase 1/2 13, Phase 1 12) 2001: 61 trials (Observational 6, Not applicable 3, Phase 4 3, Phase 3 5, Phase 2 20, Phase 1/2 7, Phase 1 17) 2002: 70 trials (Observational 6, Not applicable 5, Phase 3 6, Phase 2 23, Phase 1/2 8, Phase 1 22) 2003: 63 trials (Observational 13, Not applicable 6, Phase 4 1, Phase 3 7, Phase 2 21, Phase 1/2 5, Phase 1 10) 2004: 85 trials (Observational 14, Not applicable 6, Phase 4 1, Phase 3 14, Phase 2/3 1, Phase 2 21, Phase 1/2 8, Phase 1 20) 2005: 104 trials (Other 1, Observational 15, Not applicable 9, Phase 4 1, Phase 3 6, Phase 2 34, Phase 1/2 9, Phase 1 29) 2006: 102 trials (Observational 14, Not applicable 8, Phase 4 3, Phase 3 13, Phase 2/3 2, Phase 2 32, Phase 1/2 7, Phase 1 23) 2007: 110 trials (Observational 16, Not applicable 7, Phase 4 2, Phase 3 10, Phase 2 44, Phase 1/2 4, Phase 1 27) 2008: 110 trials (Observational 24, Not applicable 11, Phase 3 6, Phase 2 38, Phase 1/2 3, Phase 1 28) 2009: 117 trials (Other 1, Observational 15, Not applicable 11, Phase 4 2, Phase 3 6, Phase 2 40, Phase 1/2 11, Phase 1 31) 2010: 120 trials (Observational 24, Not applicable 14, Phase 3 5, Phase 2 24, Phase 1/2 17, Phase 1 36) 2011: 114 trials (Observational 15, Not applicable 15, Phase 3 11, Phase 2/3 2, Phase 2 37, Phase 1/2 9, Phase 1 25) 2012: 122 trials (Observational 19, Not applicable 30, Phase 4 2, Phase 3 7, Phase 2/3 2, Phase 2 28, Phase 1/2 8, Phase 1 26) 2013: 109 trials (Observational 24, Not applicable 24, Phase 4 5, Phase 3 4, Phase 2/3 1, Phase 2 21, Phase 1/2 13, Phase 1 17) 2014: 139 trials (Observational 33, Not applicable 32, Phase 4 3, Phase 3 5, Phase 2/3 3, Phase 2 31, Phase 1/2 11, Phase 1 21) 2015: 146 trials (Observational 26, Not applicable 33, Phase 4 13, Phase 3 9, Phase 2/3 1, Phase 2 32, Phase 1/2 9, Phase 1 23) 2016: 163 trials (Observational 27, Not applicable 39, Phase 4 5, Phase 3 10, Phase 2/3 2, Phase 2 37, Phase 1/2 13, Phase 1 30) 2017: 189 trials (Other 1, Observational 47, Not applicable 45, Phase 4 1, Phase 3 4, Phase 2 48, Phase 1/2 10, Phase 1 33) 2018: 162 trials (Observational 36, Not applicable 42, Phase 4 3, Phase 3 13, Phase 2/3 5, Phase 2 21, Phase 1/2 10, Phase 1 32) 2019: 190 trials (Observational 52, Not applicable 45, Phase 4 2, Phase 3 10, Phase 2/3 1, Phase 2 47, Phase 1/2 5, Phase 1 28) 2020: 197 trials (Observational 55, Not applicable 49, Phase 4 5, Phase 3 6, Phase 2/3 2, Phase 2 38, Phase 1/2 10, Phase 1 32) 2021: 199 trials (Observational 43, Not applicable 54, Phase 4 3, Phase 3 19, Phase 2/3 2, Phase 2 35, Phase 1/2 12, Phase 1 31) 2022: 209 trials (Observational 58, Not applicable 62, Phase 4 2, Phase 3 11, Phase 2/3 3, Phase 2 31, Phase 1/2 13, Phase 1 29) 2023: 197 trials (Observational 62, Not applicable 58, Phase 4 3, Phase 3 10, Phase 2/3 2, Phase 2 23, Phase 1/2 13, Phase 1 26) 2024: 213 trials (Observational 58, Not applicable 51, Phase 4 6, Phase 3 17, Phase 2/3 5, Phase 2 36, Phase 1/2 13, Phase 1 27) 2025: 231 trials (Observational 44, Not applicable 57, Phase 4 5, Phase 3 17, Phase 2/3 2, Phase 2 39, Phase 1/2 20, Phase 1 47)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 236
2025 231
2024 213
2023 197
2022 209
2021 199
2020 197
2019 190
2018 162
2017 189

Showing 10 of 37 earlier years.

Start your 14-day trial Email me all 37 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 270 trials starting in 2026 and about 250 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 505 trials still running at the 2026-10-09 snapshot; registered median of 41 months across 2,250 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Nervous System Neoplasms trials in? (10)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 785
Phase 1/2 289
Phase 2 959
Phase 2/3 38
Phase 3 275
Phase 4 74
Not applicable 795
Observational 835
Expanded access 20
Unknown 2

How many Nervous System Neoplasms trials are recruiting? (12)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 162
Recruiting 699
Enrolling by invitation 33
Active, not recruiting 280
Available 6

Showing 5 of 12 statuses.

Start your 14-day trial Email me all 12 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Nervous System Neoplasms trials? (4)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Cancer Institute (NCI) 234
Children's Oncology Group 52
European Organisation for Research and Treatment of Cancer - EORTC 42
Novartis Pharmaceuticals 30

Which drugs are being tested for Nervous System Neoplasms? (4)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Cytoxan 67
Irinotecan 47
NIVOLUMAB 44
PEMBROLIZUMAB 38

Interventions as named in the registry (11)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
SOC: Temozolomide 225
Radiation Therapy 177
Bevacizumab 1 94
or carboplatin 79
Etoposid 64

Showing 5 of 11 interventions.

Start your 14-day trial Email me all 11 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Nervous System Neoplasms trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Seizure 852 179
Vomiting 475 162
Platelet count decreased 425 74
Nausea 407 144
Headache 387 149

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Nervous System Neoplasms? (16)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Impact of Intrathecal Triple Therapy Versus Intrathecal Methotrexate on Disease-Free Survival for High-Risk B-Lymphoblastic Leukemia: Children's Oncology Group Study AALL1131. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2020 Yes
Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort. British journal of cancer 2019 Yes
Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. The Lancet. Oncology 2015 Yes
Nervous system involvement in von Hippel-Lindau disease: pathology and mechanisms. Acta neuropathologica 2013 Yes
Implementing routine screening for distress, the sixth vital sign, for patients with head and neck and neurologic cancers. Journal of the National Comprehensive Cancer Network : JNCCN 2013 Yes

Showing 5 of 16 publications.

Start your 14-day trial Email me all 16 publications as a PDF

Sub-conditions in MeSH (4)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages